Research Analysts Offer Predictions for RYTM Q2 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Research analysts at HC Wainwright cut their Q2 2025 EPS estimates for shares of Rhythm Pharmaceuticals in a research report issued to clients and investors on Thursday, May 8th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their prior forecast of ($0.72). HC Wainwright has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals' current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals' Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($3.01) EPS, Q1 2026 earnings at ($0.66) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($1.53) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The business had revenue of $37.72 million for the quarter, compared to analysts' expectations of $40.43 million. During the same period last year, the business earned ($2.35) EPS. The company's revenue for the quarter was up 25.9% on a year-over-year basis.

A number of other equities research analysts have also recently issued reports on the stock. Morgan Stanley reissued an "overweight" rating and issued a $72.00 price target on shares of Rhythm Pharmaceuticals in a research note on Friday, March 7th. Needham & Company LLC boosted their target price on shares of Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group upped their price target on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Bank of America upgraded Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective for the company in a research note on Monday, April 7th. Finally, Stifel Nicolaus assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Wednesday, March 5th. They set a "buy" rating and a $78.00 target price on the stock. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $75.38.

Rhythm Pharmaceuticals Trading Up 0.5%

RYTM traded up $0.32 on Monday, reaching $60.50. The stock had a trading volume of 121,342 shares, compared to its average volume of 550,996. The business's 50-day moving average price is $57.53 and its two-hundred day moving average price is $57.24. The company has a market cap of $3.85 billion, a P/E ratio of -13.99 and a beta of 2.36. Rhythm Pharmaceuticals has a 12-month low of $35.17 and a 12-month high of $68.58.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. SRS Capital Advisors Inc. raised its stake in shares of Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after buying an additional 400 shares in the last quarter. Raleigh Capital Management Inc. acquired a new position in Rhythm Pharmaceuticals during the fourth quarter worth about $28,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Rhythm Pharmaceuticals in the first quarter valued at about $34,000. SBI Securities Co. Ltd. acquired a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $37,000. Finally, R Squared Ltd purchased a new position in Rhythm Pharmaceuticals during the 4th quarter valued at about $44,000.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 7,031 shares of the company's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $65.09, for a total transaction of $457,647.79. Following the completion of the transaction, the insider now owns 19,209 shares in the company, valued at approximately $1,250,313.81. This represents a 26.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph Shulman sold 1,228 shares of Rhythm Pharmaceuticals stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $70,266.16. Following the completion of the sale, the insider now directly owns 8,509 shares in the company, valued at approximately $486,884.98. The trade was a 12.61% decrease in their position. The disclosure for this sale can be found here. Insiders sold 143,639 shares of company stock valued at $8,023,381 over the last three months. 5.60% of the stock is owned by corporate insiders.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.